Table 3 Mean costs per patient during observation period (no discounting)
From: Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
Item | S-1 therapy | Surgery alone | ||
|---|---|---|---|---|
Unit cost ($) | Quantity | Cost ($) | Quantity | Cost ($) |
| Â | (No. of units) | (No. of units) | ||
Consultation | Â | Â | Â | Â |
   Outpatient: 5.8 | 22.4 | 131 | 8.3 | 49 |
Treatment | Â | Â | Â | Â |
   S-1 drug (mg): 0.3 | 15,156 | 4,367 | NA |  |
Prescription: 4.9 | 10.5 | 52 | NA | Â |
Tests | Â | Â | Â | Â |
  Imaging tests |  |  |  |  |
   CT: 124.3 | 5.1 | 629 | 4.9 | 608 |
   Chest X-ray: 21.1 | 2.0 | 42 | 2.0 | 43 |
   Echogram: 44.2 | 1.8 | 80 | 1.9 | 85 |
   Endoscopy: 95.0 | 1.5 | 147 | 1.7 | 164 |
   Others: 156.0 | 0.2 | 34 | 0.2 | 38 |
  Laboratory tests |  |  |  |  |
  Blood test: 35.0 | 21.3 | 746 | 9.1 | 319 |
  Tumor markers: 33.3 | 8.6 | 286 | 8.6 | 288 |
Adverse effects | Â | Â | Â | Â |
Anti-ulcerants: 6.0 | 0.3 | 2 | 0.2 | 1 |
Anti-biotics: 15.4 | 0.2 | 3 | 0.1 | 1 |
Anti-diarrhoeals: 5.4 | 0.2 | 1 | 0.1 | 0 |
Anti-emetics: 64.8 | 0.1 | 9 | 0.0 | 3 |
G-CSF: 106.9 | 0.0 | 3 | 0.0 | 0 |
Blood transfusion: 188.5 | 0.0 | 0 | 0.0 | 1 |
Recurrence | Â | Â | Â | Â |
S-1: 3,694 | 0.1 | 487 | 0.3 | 1,394 |
Paclitaxel: 5,298 | 0.1 | 422 | 0.0 | 101 |
S-1 + cisplatin: 5,594 | 0.0 | 227 | 0.1 | 244 |
S-1 + paclitaxel: 5,247 | 0.0 | 162 | 0.0 | 129 |
5FU + methotrexate: 4,748 | 0.0 | 65 | 0.0 | 144 |
Irinotecan + cisplatin: 5,197 | 0.0 | 162 | 0.0 | 43 |
Others: 4,892 | 0.0 | 211 | 0.0 | 201 |
End of life | Â | Â | Â | Â |
Drugs/injections | 0.3 | 1,064 | 0.4 | 1,367 |
Treatments | 0.3 | 233 | 0.4 | 321 |
Operations/anesthesia | 0.3 | 213 | 0.4 | 296 |
Diagnostic tests | 0.3 | 221 | 0.4 | 353 |
Total costs per patient | 11,103 | 7,761 | ||
(SD) | (6,832) | (6,787) | ||